# Treatment approaches for severe sarcoidosis
Treatment of severe sarcoidosis focuses on suppressing the abnormal inflammatory response that causes granulomas, and on preventing or slowing scar formation in organs. Because sarcoidosis can be highly variable and can affect different organs in different ways, the approach is always tailored. The goal is to relieve symptoms, protect damaged functions, and prevent further progression.
Corticosteroids
ProveniIncluded in official guidelines, or approved by EMA or FDA
Corticosteroids are the first choice in severe sarcoidosis, especially when the heart, nervous system, or eyes are seriously involved. They suppress the inflammatory response by reducing the activation of immune cells and preventing granuloma formation. They work relatively quickly and are usually given by mouth, in decreasing doses over time.
The main side effects with long-term use are weight gain, insomnia, mood swings, elevated blood sugar, weakening of bones (osteoporosis), and increased risk of infection. Because these side effects can increase the longer the medication is used, treatment providers usually try to gradually reduce the dose once the disease is under control. Use requires regular checks of blood sugar levels, bone density, and blood pressure.
Immunosuppressive agents (classical)
ProveniIncluded in official guidelines, or approved by EMA or FDA
When corticosteroids alone are not sufficient, or when side effects become bothersome, immunosuppressive agents are added or used as a replacement. The most commonly used are methotrexate and azathioprine. These suppress the function of certain immune cells and prevent new granulomas from forming.
Methotrexate works gradually (usually several weeks to months before effects are noticeable) and reduces the amount of inflammatory proteins. Azathioprine works at a different point in the immune system. Both require regular blood tests to monitor inflammatory values and liver function. Possible side effects are gastrointestinal complaints, anemia, increased susceptibility to infections, and rarely serious liver or kidney complications. Because these agents work slowly, they are usually given together with corticosteroids initially.
Biological therapies (TNF-alpha inhibitors)
ProveniIncluded in official guidelines, or approved by EMA or FDA
For severe sarcoidosis that does not respond well to corticosteroids or classical immunosuppressive agents — especially if the heart, eyes, or nervous system are involved — TNF-alpha inhibitors are used. These neutralize a specific inflammatory signal that plays a key role in granuloma formation. The most studied are infliximab and adalimumab.
These agents are given intravenously (infliximab) or by injection under the skin (adalimumab). They can work remarkably quickly, sometimes within weeks. An important side effect profile: increased risk of opportunistic infections (including tuberculosis), impaired responses to vaccines, and rarely cytopenias (reduced blood or inflammatory cells). Therefore, tuberculosis screening is done before use. Additionally, inflammation-related antibodies can develop that make the agent less effective. In recent case reports, it has been described that even TNF inhibitors sometimes prove insufficient against very severe forms, indicating that individual response is highly variable.
Biological therapies (co-stimulation inhibitors)
ResearchediPositive results in clinical studies, not yet standard treatment
Abatacept and belatacept belong to a newer class that disrupts communication between certain immune cells. Studies from 2026 point to potential use in immune-mediated diseases, including sarcoidosis, especially when inflammatory pathways are TNF-independent. These agents are not yet included as standard therapy in all guidelines, but clinical trials are underway. They target a different part of the immune system than TNF inhibitors, which may help when resistance or side effects from other biologicals become problematic.
Side effects appear somewhat milder than TNF inhibitors, but infection risk remains a point of concern. More experience is needed before its clear place in the standard regimen is determined.
Supplementary treatment in cardiac sarcoidosis
ProveniIncluded in official guidelines, or approved by EMA or FDA
When sarcoidosis affects the heart, anti-inflammatory agents are combined with heart-specific therapies. Arrhythmias can be treated with antiarrhythmic medications or implantable defibrillator-pacemakers. Heart failure is managed with ACE inhibitors, beta-blockers, and other medications. These are not sarcoidosis-specific, but are life-saving when heart tissue is damaged.
The focus is on: controlling the granulomas and inflammation (with corticosteroids and immunosuppressants) and treating the consequences of damage. In severe cases, cardiac regeneration may be limited, so transplantation can be considered in exceptional situations.
Supplementary treatment in pulmonary sarcoidosis with fibrosis
ProveniIncluded in official guidelines, or approved by EMA or FDA
(anti-inflammatory treatment)
ResearchediPositive results in clinical studies, not yet standard treatment
(antifibrotic agents)
When sarcoidosis leaves scars on the lungs, both the underlying granulomatous inflammation and the fibrosis process must be addressed. Corticosteroids and immunosuppressants address granuloma formation. For fibrosis itself, antifibrotic agents are sometimes used (such as pirfenidone or nintedanib), although their role in sarcoidosis is being studied more intensively than in idiopathic pulmonary fibrosis. These reduce the progression of scar tissue formation.
Side effects of antifibrotic agents include fatigue, gastrointestinal complaints, and increased susceptibility to infections. The evidence for sarcoidosis-related fibrosis is weaker than for the idiopathic form, because sarcoidosis itself is heterogeneous.
Treatment of symptomatic findings
ProveniIncluded in official guidelines, or approved by EMA or FDA
In addition to underlying immune suppression, symptoms are addressed directly. Pain is treated with analgesics, cough with cough suppressants, fatigue with attention to sleep and exertion. Eye inflammation may require local corticosteroid drops. Kidney stone disease and calcium metabolism require fluid intake and sometimes agents that regulate calcium absorption.
These supportive measures relieve quality of life and prevent secondary complications, but do not address sarcoidosis itself.
Experimental and investigational phases
Recent trials (2026) show new monoclonal antibodies under investigation, including XTMAB-16 and OATD-01, targeting different inflammatory pathways in pulmonary sarcoidosis. Researchers are also exploring the potential of imaging techniques such as FAPI-PET to monitor granuloma activity and better predict response to therapy.
These treatments are not yet routinely available and are only given in the context of studies. They may become relevant for individual patients with difficult-to-control disease, should approval follow.
Monitoring and dose reduction of therapy
ProveniIncluded in official guidelines, or approved by EMA or FDA
Clinicians regularly check whether therapy is effective via blood tests, imaging (chest X-ray, CT, PET), and clinical assessment. When the disease is under control, they attempt to gradually reduce corticosteroid doses and sometimes discontinue immunosuppressants to minimize long-term side effects. Some patients may eventually reach low-dose monitoring; others require lifelong maintenance.
It is a dynamic process: relapse can occur, so adjustments are made based on current findings and symptoms.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._